Biologia

Shutting out Soft Tissue Cancers in the Cold
Cryotherapy, an interventional radiology treatment to freeze cancer tumors, may become the treatment of the future for cancer that has metastasized in soft tissues (such as ovarian cancer) and in bone tumors. Such patients are often not candidates for surgery and would benefit from minimally invasive treatment, say researchers at the Society ofInterventional Radiology's 35th Annual Scientific Meeting in Tampa, Fla.

"Improved treatment options are needed for individuals affected by metastases in bone and soft tissues since patients with multifocal metastatic disease are often not candidates for surgery," said Peter J. Littrup, M.D., an interventional radiologist and director of imaging research and image-guided therapy for the Barbara AnnKarmanos Cancer Institute in Detroit, Mich. "Percutaneous soft tissue cryotherapy is a well-tolerated treatment option, especially for patients with anesthesia risks, painful lesions or those seeking local control during chemotherapy. Tumor size and/or location do not preclude thorough treatment or pose greater risk with appropriate precautions," added Littrup, who is also a professor of radiology,urology and radiation oncology at Wayne State University in Detroit.

In the 97-patient study, researchers used sufficient deadly temperatures to effectively kill tumor cells, resulting in an average of 77 percent tumor shrinkage in patients after 24 months. "Because of the variable placement of tumors within these soft tissue and bone locations, this study shows the versatility of thistreatment option when using proper techniques to safeguard nearby structures. Aside from the successful tumor control, what makes this technique even more preferable is the excellent tumor shrinkage since the underlying fibrous or collagenous structures are preserved. The body can then better heal at the ablation (removal) site with minimal additional scar tissue formation," said Littrup.

Last year,it was estimated that 1.5 million new cases of cancer were diagnosed, and up to 85 percent of patients who have breast, prostate or lung cancer have bone metastases at the time of death. Additionally, 5 percent of all cancers result in skin cancer as well. Based on these numbers, conservative estimates determine that up to 500,000 of these newly diagnosed cancer patients alone will suffer frommetastatic disease in bone and soft tissue areas.

Cryotherapy is a good option for a large -- but perhaps under-recognized -- problem that could deliver a quantum impact. Namely, the original cancer tumor site (or even a few unresponsive tumors sites) can still cause cancer management problems even after a generally good response to chemotherapy and/or radiation therapy, said Littrup. "Metastasizedtumors can occur nearly anywhere in the body and frequently cannot receive additional radiation therapy or would be difficult or very morbid to be controlled with surgery," said Littrup. "Cryotherapy was able to preserve quality of life by providing good local treatment with minimal side effects, especially with advanced stages of cancer where any additional treatment is unlikely to provide asystemic cure," he added. However, cryotherapy is not a first-line therapy for tumor treatment. Despite "superb" cryotherapy outcomes for many tumor types and locations, medical insurance may not cover the treatment, said Littrup.

Historically, cyoablation has been performed on the prostate and liver, but this technique has been recently found effective in other tumors including the breast, kidneyand lung. "We simply translated this concept to retroperitoneal, intraperitoneal, superficial and bone locations in order to generate successful use of cryotherapy in different patient groups," said Littrup. The major benefits of cryotherapy are its superb visualization of the ice treatment zone during the procedure, its low pain profile in an outpatient setting and its excellent healing with...